Adoption has been slow with new Alzheimer’s drugs because the treatments are complicated to administer and the benefits are uncertain.
Medicare payments for Alzheimer’s medications are coming in well below forecasts.Suzanne Kreiter/Globe staff
By Bob Herman
May 11, 2026
Bob Herman is the author of Health Care Inc., an award-winning weekly newsletter about the business of health and medicine.
Bob Herman
Gli agenti IA entrano nella sanità, ma il nodo è il rimborso
Medicare's new payment model is built for AI, and most of the tech world has no idea | TechCrunch
Billions In Prescriptions Go Unfilled. This Startup Is Using AI To Fix That.
Pflege: Das kostet es, Angehörige zu pflegen
So teuer kann die eigene Pflege im Alter werden
CVS blows past estimates, hikes outlook as insurance business outperforms
Friday, May 8, 2026: Cramer says he'll keep buying this healthcare stock as the sector remains weak
Experts Warn These Early Dementia Signs Often Get Missed — But Early Detection Makes A Big Difference
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
